0000000000659636

AUTHOR

Alex Federico

showing 4 related works from this author

205 Minimally invasive approaches in locally advanced cervical cancer patients undergoing radical surgery after chemoradiotherapy: a propensity score…

2020

Objectives To evaluate the oncological and surgical outcome of minimally invasive radical surgery (MI-RS) compared to open radical surgery (O-RS) in locally advanced cervical cancer (LACC) after preoperative chemoradiation (CT/RT). Methods Data relative to stage IB2-IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Starting from 686 patients, the propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade and clinical response to CT/RT. Overall, 107 recurrences were registered with no difference in the pattern of recurrences between the two surgical approaches. The 5-year diseas…

Cervical cancermedicine.medical_specialtybusiness.industryLocally advancedDiseasemedicine.diseaseSurgerymedicine.anatomical_structurePropensity score matchingmedicineRadical surgeryStage (cooking)businessLymph nodeChemoradiotherapyPoster
researchProduct

Minimally Invasive Approaches in Locally Advanced Cervical Cancer Patients Undergoing Radical Surgery After Chemoradiotherapy: A Propensity Score Ana…

2020

Abstract Purpose Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role in locally advanced cervical cancer (LACC) patients with suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Our aim is to evaluate oncological and surgical outcomes of minimally invasive radical surgery (MI-RS) compared with open radical surgery (O-RS). Patients and Methods Data for stage IB2–IVA cervical cancer patients managed by CT/RT and RS were retrospectively analyzed. Results Beginning with 686 patients, propensity score matching resulted in 462 cases (231 per group), balanced for FIGO stage, lymph node status, histotype, tumor grade, and clinical respons…

medicine.medical_specialtymedicine.medical_treatmentConcomitant Chemoradiation Neoadjuvant Chemotherapy Phase III Hysterectomy Radiation Therapy WomenUterine Cervical NeoplasmsHysterectomyDisease-Free Survival03 medical and health sciences0302 clinical medicinePhase IIIlocally advanced cervical cancer (LACC)locally advanced cervical cancerHumansMedicineWomenChemoradiotherapy; Disease-Free Survival; Female; Humans; Hysterectomy; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Staging; Propensity Score; Retrospective Studies; Uterine Cervical Neoplasms030212 general & internal medicineStage (cooking)Radical surgeryPropensity ScoreNeoadjuvant therapyNeoplasm StagingRetrospective StudiesCervical cancerHysterectomyRadiationbusiness.industrylocally advanced cervical cancer surgeryNeoadjuvant ChemotherapyRetrospective cohort studyChemoradiotherapyGynecologic Oncologymedicine.diseaseNeoadjuvant TherapySurgeryRadiation therapySettore MED/40 - GINECOLOGIA E OSTETRICIANeoplasm RecurrenceLocalOncology030220 oncology & carcinogenesisConcomitant ChemoradiationFemaleSurgeryTherapyNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Robotic versus laparoscopic radical hysterectomy in early cervical cancer: A case matched control study

2018

Abstract Background This study aims at evaluating the feasibility, surgical outcome and oncological results observed after robotic radical hysterectomy (RH) compared to laparoscopy for patients with early stage cervical cancer (ECC) patients. Methods Between January 2010 and October 2016, 210 patients underwent RH for treatment of ECC: 70 underwent robotic approach (Cases), and 140 underwent laparoscopic approach (Controls). Results There was no statistically significant difference between the two approaches with regard to clinical patient characteristics and in terms of extent of RH and rate of pelvic and aortic lymphadenectomy. Operative time was significantly longer in the robotic versus…

Uterine Cervical NeoplasmTime Factorsmedicine.medical_treatmentEarly stage cervical cancerUterine Cervical Neoplasms0302 clinical medicinePostoperative ComplicationsRetrospective StudieLaparotomy80 and overMedicineEarly Detection of CancerEarly stage cervical cancer; Laparoscopy; Robotic surgery; Adult; Aged; Aged 80 and over; Female; Humans; Hysterectomy; Incidence; Italy; Laparoscopy; Middle Aged; Postoperative Complications; Retrospective Studies; Robotics; Survival Rate; Time Factors; Uterine Cervical Neoplasms; Young Adult; Early Detection of Cancer; Neoplasm Staging; Surgery; OncologyAged 80 and over030219 obstetrics & reproductive medicineIncidenceGeneral MedicineRoboticsMiddle AgedSurvival RateOncologyItaly030220 oncology & carcinogenesisFemaleHumanAdultmedicine.medical_specialtyTime FactorHysterectomy03 medical and health sciencesYoung AdultHumansRobotic surgeryRadical surgeryRadical HysterectomySurvival rateRetrospective StudiesAgedNeoplasm StagingHysterectomybusiness.industryRobotic surgeryPerioperativeSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIASurgeryLymphadenectomyLaparoscopyPostoperative Complicationbusiness
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct